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Abstract
Background: Wee1 kinase plays a critical role in maintaining G2 arrest through its inhibitory phosphorylation
of cdc2. In previous reports, a pyridopyrimidine molecule PD0166285 was identified to inhibit Wee1 activity at
nanomolar concentrations. This G2 checkpoint abrogation by PD0166285 was demonstrated to kill cancer cells,
there at a toxic highest dose of 0.5 μM in some cell lines for exposure periods of no longer than 6 hours. The
deregulated cell cycle progression may have ultimately damaged the cancer cells. We herein report one of the
mechanism by which PD0166285 leads to cell death in the B16 mouse melanoma cell line.
Methods: Tumor cell proliferation was determined by counting cell numbers. Cell cycle distribution was
determined by flow cytometry. Morphogenesis analysis such as microtubule stabilization, Wee1 distribution, and
cyclin B location were observed by immunofluorescence confocal microscopy. An immunoblot analysis of cdc2-
Tyr15, cyclin D, E, p16, 21, 27, and Rb. A real-time PCR of the mRNA of cyclin D were completed.
Results: In our experiment, B16 cells also dramatically abrogated the G2 checkpoint and were found to arrest
in the early G1 phase by treatment with 0.5 μM for 4 hours observed by flow cytometry. Cyclin D mRNA
decreased within 4 hours observed by Real-time PCR. Rb was dephosphrylated for 24 hours. However, B16 cells
did not undergo cell death after 0.5 μM treatment for 24 hours. Immnofluoscence microscopy showed that the
cells become round and small in the morphogenesis. More interesting phenomena were that microtubule
stabilization was blocked, and Wee1 distribution was restricted after treatment for 4 hours.
Conclusion: We analyzed the effect of Wee1 inhibitor PD0166285 described first by Wang in the G2 transition
in the B16 melanoma cell line. The inhibitor PD0166285 abrogated G2/M checkpoint inducing early cell division.
Moreover, we found that the treatment of cells with the inhibitor is related to microtubule stabilization and
decrease in cyclin D transcription. These effects together suggest that Wee1 inhibitor may thus be a potentially
useful anti-cancer therapy.
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The progression of the mammalian cell cycle is controlled
by the sequential activation of a series of cell cycle-
dependent kinases (CDKs) [1]. Dysfunction of these
molecular checkpoints results in the proliferation of can-
cer cells. In this context, an abrupt shift of the cell to mito-
sis from the G2 phase has received increasing attention, as
have elements of the G2 checkpoint, particularly Wee1
[2].
The activation of the mitosis-promoting kinase cdc2 is
required for transition from the G2 to the G1 phase in all
eukaryotic cells. Cdc2 is subject to multiple levels of regu-
lation, including association with its major partner B-type
cyclin, reversible phosphorylation, and intracellular com-
partmentalization. After association of cdc2 with cyclin B,
activity of cdc2-cyclin B is repressed to a basal level until
G2/M transition, when the G2/M checkpoints are com-
plete [3,4]. Phosphorylation of cdc2 at Thr-14 and Tyr-15
is critical in the repression of cdc2-cyclin B. The protein
kinase Wee1 [5,6] phosphorylates at Tyr-15, while
another protein kinase membrane-associated cdc2 tyro-
sine- and threonine-specific cdc2 inhibitor (Myt1) phos-
phorylates both site [6,7]. Cdc25C, on the other hand, is
a phosphatase that dephosphrylates cdc2 at Thr-14 and
Tyr-15. As a result cyclin B-cdc2 is activated and the cell
cycle progresses. Because the Thr-14 and Tyr-15 phospho-
rylations are crucial for function of the G2/M checkpoint
[8], induction of G2 arrest may require activation of Wee1
and Myt1 in addition to inactivation of Cdc25C [9].
Human Wee1 is inactivated through phosphorylation and
protein degradation during the M phase. This degradation
of Wee1, carried out through ubiquitination by cdc34
[10] and the ubiquitin ligase complex (Skp1, CDC53/Cul-
lin, F-box protein) [11], also is regulated by cdc2-cyclin B
[12]. Typically, irradiation-induced DNA damage favors
inactivation of Cdc25C as follows. The mechanism by
which Cdc25C is inactivated involves phosphorylation at
Ser-215 catalyzed by Chk1/Chk2, and a 14-3-3 exportion
from nuclei. The upstream kinase that activates Chk1 is
ATM, which can be activated by DNA damage. Such
Cdc25C inactivation helps to maintain cell cycle arrest by
Wee1. Another possibly relevant pathway involves the
DNA damage response kinases, checkpoint kinase (Chk1)
and serine/threonine-protein kinase (Cds1), which
directly phosphorylate Wee1. However, the physiologic
significance of this phosphorylation remains obscure
[13,14].
After mitosis, daughter cells adhere to the extracelluler
matrix. Cyclin D, which acts to initiate the cell cycle, then
is expressed. Cyclin D expression is important for progres-
sion through the G1 phase. Expressions of cyclin D
increased due to various stimuli. Initially, cyclin D is
increased by the Rac-integrin signal associated with cell-
to-cell matrix adhesion. After some hours, cyclin D expres-
sion is regulated through Erk signaling by growth factors
[15]. Cyclin D combines with CDK4/6, cyclin E/CDK2
and cyclin A/CDK2 [16]. The cell will then advance into
the G1 phase. E2F, which regulates the trasnscription of
various molecules, is activated through phosphorylation
inactivating Rb by CDKs; cells then advance into the S
phase [17].
PD0166285, a ppyrido [2,3-d] pyimidine compound, was
developed [18] as an inhibitor of Wee1; inhibition is evi-
dent even at nanomolar concentrations. Irradiation
induces DNA injury, so cell arrest which prevent cell
apoptosis. This is one of the reasons that effect of inducing
apoptosis to cancer cells is restricted in radiation therapy.
In seven cancer cell lines, 0.5 μM of PD0166285 for short
exposure period (2–4 hour) was found to dramatically
inhibit the radiation-induced cdc2 phosphorylation,
which otherwise would have resulted from Cdc25C inac-
tivation. Before the G2/M transition leading to cell divi-
sion, Wee1 reversibly arrests the cell cycle by inactivating
cdc2 through phosphorylation at Tyr-15. PD0166285
may thus nullify the G2 checkpoint. Because Wee1 is
inhibited, cancer cells do not undergo cell cycle arrest, so
mitosis continues despite radiation-induced injury to
DNA. However, in cells susceptible to p53 and the G1
check point killing, PD0166285 acts as a radiosensitizer
promoting cell death. The sensitivity enhancement ratio
was found to be 1.23 by a clonogenic assay. Interestingly,
this radiosensitizing activity is p53 dependent, thus show-
ing greater efficacy in cells where p53 is active. This inhib-
itor represents a novel class of anticancer drugs that
selectively enhance cancer cell killing by conventional
therapies.
However, PD0166285 kills tumor cells directly in some
cell lines at a toxic highest dose of 0.5 μM for long expo-
sure periods of no more than 6 hours with no relation of
p53. These effects were observed in many cell lines such as
ovarian carcinoma PA-1 cells, colon cancer HT29,
HCT116, cervical cancer HeLa, lung carcinoma H460
[18], and hepatoma cell line Hep3B [19].
In this report, after treatment with PD0166285, B16 cells
were also arrested in the early G1 phase within at least 4
hours. Here we indicate novel antiproliferative activities
to block adhesion of the Wee1 inhibitor PD0166285 hav-




B16 mouse melanoma cells were maintained in Dul-
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bovine serum, (FBS).
Cell counting
Cell proliferation was analyzed by counting the cells. B16
cells (1 × 105 cells in 100 mm-dishes) were maintained in
medium overnight. In addition, the cells were treated with
(0, 0.5, 1.0, or 2.0 μM) PD0166285 (including DMSO
vehicle) for indicated times. The cells were washed twice
with phosphate-buffered saline (PBS). Next, the cells were
trypsinized, so the cell numbers in each dish were deter-
mined by using a computed cell-counter (Sysmex CDA-
500) according to manufacturer's recommendation.
Drug
The Wee1 inhibitor, PD0166285, was kindly provided by
Pfizer (Ann Arbor, MI).
Antibodies
The present study used: antibodies against cyclin D, cyc-
lin, p16, Wee1, Rb, and anti-α-tubulin (Santa Cruz Bio-
technology, Santa Cruz, CA), and against p21 and p27
(Transduction Laboratories, San Diego, CA). Phospho-
Plus cdc2 (Tyr15) antibody kit was obtained from New
England BioLab (Beverly, MA).
Flow Cytometry and Cell Cycle Analysis
After treatment with 0.5 μM PD0166285, B16 cells were
trypsinized, washed with PBS, and incubated in 0.2% Tri-
ton X-100 for 20 min at 37°C. After incubation, cells were
treated with propidium iodideide (PI) and then subjected
to DNA content analysis. PI florescence was analyzed with
a FACScalibur flow Cytometer (Becton Dickinson). Find-
ings characterizing flow for at least 20,000 cells were col-
lected and analyzed with Cell Quest software (Becton
Dickinson). Cell cycle distributions were calculated with
Mod Fit LT software (Becton Dickinson).
Morphologic observation by immunofluorescence 
confocal microscopy
Cells were incubated in glass-bottom microwell dishes
(poly-d-Lysine coated, 35 mm) for at least 4 hours, with
or without 0.5 μM PD166285. α-tubulin: Cells were
washed with PBS, fixed in 4% paraformaldehyde in PBS
for 20 min at room temperature, and permeabilized in
0.2% TritonX-100 for 10 min at room temperature. After
treatment against nonspecific binding with blocking pro-
tein (DAKO, Carpenteria, CA) for 20 min at room temper-
ature, cells were incubated with anti-α-tubulin antibody
(1:400) overnight at 4°C and then with FITC-conjugated
secondary antibody for 1 hour at room temperature. After
washing with PBS, cells were incubated with PI for 5 min
at room temperature to stain the nucleus. Observation
was carried out with a laser-scanning confocal immun-
ofluorescence microscope (Olympus, Tokyo, Japan).
Wee1: Cells grown in glass bottom microwell dishes
(poly-d-Lysine coated, 35 mm) were fixed in 50:50 (vol/
vol) methanol/acetone and incubated with anti-Wee1
antibody at a 1:250 dilution overnight at 4°C. FITC-con-
jugated secondary antibody was then added for 1 hour at
room temperature. Cells were counter stained with PI or
double-stained with anti-α-tubulin as observed above.
Immunoblotting analysis
Cells were lysed in lysis buffer (50 mM HEPES at pH 7.5,
250 mM NaCl, 20 mM EDTA, and 0.1% Nonidet P-40)
additionally containing 1 mM phenylmethylsulfonyl flu-
oride, a protein inhibitor cocktail (Sigma, St. Louis, MO),
10 nM NaF, and 1 mM Na3VO4. Lysates were incubated at
4°C for 15 min and then cleared of cell debris by centrif-
ugation at 14,000 g for 15 min at 4°C. Supernatants were
subjected to protein determinations using a DC protein
assay kit (Bio-RAD Laboratories, Hercules, CA) according
to the manufacturer's instructions. Total cell lysates were
then added to an equal volume of 2 × sample loading
buffer containing 2% sodium dodecyl sulfate (SDS) and
boiled for 5 min. Total cell protein was then loaded onto
SDS-polyacrylamide gels for electrophoresis. Proteins
were electrically transferred to Fluorotrans membranes for
immunoblotting. The membrane was blocked for 1 hour
at room temperature with 5% nonfat dry milk and then
incubated with primary antibody overnight at 4°C. The
membrane was washed, and incubated with horseradish
peroxidase-labeled secondary antibody for 1 hour at room
temperature. Finally the membrane was incubated with a
detection reagent kit including luminol in an alkaline
buffer, according to manufacturer's recommendations.
(Amersham Pharmacia Biotech, Piscataway, NJ). Specific
bands were visualized by allowing the membrane to
expose blue- light-sensitive autoradiographic films.
Total RNA extraction, cDNA synthesis, and reverse 
transcription (RT)-polymerase chain reaction (PCR)
For total RNA isolation, cultured cells were extracted using
the Isogen method (Nippon Gene, Tokyo, Japan). RNA
was quantified by spectrophotometry. Complementary
DNA (cDNA) was synthesized using 2 μg of total RNA
with random primers and Superscript III reverse tran-
scriptase (Invitrogen, Carlsbad, CA). The RNA and prim-
ers were denatured by heating at 70°C for 10 min. The RT
reaction mixture was then incubated for 30 min at 50°C,
followed by 15 min at 70°C. A template-free control was
processed for each experiment, establishing an absence of
genomic contamination in the samples. The resulting
cDNA then was amplified by PCR (20 cycles) with primer
pairs specific for cyclin D, or glyceraldehyde-3-phosphate
dehydrogenase. PCR products were resolved in 1.5% aga-
rose gels and visualized by ethidium bromide staining
with ultraviolet transillumination. PCR cycle conditions
were 94°C for 30 s, 6°C for 30 s and 72°C for 1 min. ThePage 3 of 11
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GAGACCGGCAGTACAG-3' and 5'-TTGCAGCAGCTC-
CTCGGGC-3' (512 bp), and GAPDH, 5'-
ACCACAGTCCATGCCATCAC-3' and 5'-TCCACACCCT-
GTTGCTGTA-3' (452 bp).
SYBR Green real-time quantitative PCR
For quantitative SYBR Green real-time PCR, 0.6 μl of the
RT products were used for each reaction, carried out using
a SYBR Green PCR Core Reagent kit (PE Biosystems, War-
rington, UK) according to the protocol provided by the
manufacturer. Optimal conditions were established for
each specific gene. Primer sequences were designed for
cyclin D as follows using Primer Express Software (PE
Applied Biosystems, Foster City, CA): 5'-GCAGCACCCG-
GTCGTTGAGGA-3' and 5'-TCCGGAGACCGGCAGTACA-
3' (180 bp). After quantitative PCR was performed, prod-
ucts were analyzed using the ABI PRISM 7000 Sequence
Detection System (PE Applied Biosystems). A three-stage
PCR cycle program provided by the manufacturer was
used, as follows: 2 min at 50°C, 10 min at 95°C, and then
40 cycles of 15 s at 95°C and 1 min at 60°C. Reaction
products were visualized on ethidium bromide-stained
1.5% agarose gels. Appearance of a single band of the cor-
rect molecular size confirmed PCR specificity. Results are
representative of three independent experiments [20].
Results
PD0166285 suppressed cell proliferation by inducing G0/1 
cell cycle arrest
Cell proliferation was analyzed by counting the cell num-
bers. We counted the cell number with DMSO control,
0.5, 1, and 2 μM treatment for 4 hours and 24 hours. 0.5
μM of PD0166285 was bottom line to anti-proliferate
(Figure 1A). Cell cycle changes were investigated using
flow cytometry. B16 cells were arrested in the early G1
stage after treatment with 0.5 μM PD0166285. No cells
showing characteristics of apoptosis were observed (Fig-
ure 1B). The percentage of cells in the G0/G1 phase was
67% at 0 hours after PD0166285 treatment, and 86% at 4
hours. The percentage in the S phase was 16% at 0 hours,
and 12% at 4 hours. The percentage in the G2 phase was
17% at 0 hours, and 2% at 4 hours. S-, G2-, and M-phase
cells progressed to the early G1 phase within 4 hours.
PD0166285 thus promoted complex cell cycle progres-
sion from G2 to the G1 phase in B16 cells. At 24 hours,
the G1, S and G2 cell distributions were 81, 15 and 4%,
respectively after PD0166285 treatment with 0.5 μM. In
DMSO control, the percentage of cells was almost same
within 0 h to 24 h. Sub-G1 which means that apoptosis
was absent at 24 hours.
PD0166285 inhibited microtubule stabilization
Double-staining immunofluorescence microscopy with
PI (red) and anti-α-tubulin (green) after 4 hours of
PD0166285 treatment is shown in Figure 2A. Nuclei in
most of the cells had become small and the cell number
had increased. However, the cells did not spread. Typical
interphase microtubule networks had disappeared at 4
hours. Photomicrographs at 0 hours, 2 hours, and 4 hours
show disappearances of microtubule networks in those
cells not exhibiting mitosis (Figure 2B). PD0166285 thus
inhibited microtubule stabilization. The amount of α-
tubulin protein in cells with and without PD0166285
treatment remained the same (DATA not shown).
PD0166285 inhibited Wee1 activity and progressed from 
the G2 to G1 phase
PD0166285 almost completely abolished cdc2-Tyr15
phosporylation in B16 cells (Figure 3A). Expression of
cdc2 were no change, but the expression of cyclin B
decreased. We then characterized the cellular localization
of cyclin B by laser confocal immunofluorescence micros-
copy. At 4 hours, cyclin B expression was diminished,
although it could be seen in most cells in the early G1
phase (Figure 3B)
Localization of Wee1 showed expression upon cell 
adhesion
We characterized Wee1 in terms of its subcellular location
in the cytoplasm, and also changes evident upon cell
adhesion. Without PD0166285 treatment, Wee1 was seen
extensively in the cytoplasm. Upon PD0166285 treat-
ment, Wee1 was clustered tightly around nuclei while
cells appeared shrunken (Figure 4A). Wee1 and α-tubulin
were cellular co-localization molecules. After treatment,
they were restricted in distribution. The spreading of cell
and plasma membrane ruffling were suppressed in mor-
phogenesis (Figure 4B). This indicated imperfect adhe-
sion.
Cell cycle-related proteins were altered
To address the mechanisms of cell cycle arrest induced by
PD0166285 in B16 cells, expression of endogenous CDK
inhibitors (CKIs) such as p16, p21, and p27 were investi-
gated by immunoblot analysis with specific antibodies for
CKIs (Figure 5A). P16 protein was not detected. P21 and
p27 were detectable, but amounts were unchanged at also
24 houres (Figure 5B). Progression through the cell cycle
is governed by kinase activities of specific CDKs, which are
regulated by association with the regulatory cyclin subu-
nits. We investigated cyclin D and E, which are related to
the progression from the G1 to the S phase. The progres-
sion through the G1 phase involves mainly CDK4/6-cyc-
lin D in the early G1 phase and CDK2-cyclinE in the mid
G1 phase. Cyclin D decreased gradually until 4 hours.
Cyclin E was found to decrease at 2 hours, but then it
somewhat increased at 4 hours. P16, an inactivator of
CDK4/6-cyclin D, was not detected in B16 cells. There-
fore, it is known that cell cycle arrest is the suppression ofPage 4 of 11
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investigated Rb, which regulates cell cycle progression
from G1 to the S phase via E2F after treatment for 0, 4 and
24 hours. An immunoblot analysis showed a gradually
inactive dephosphorylation of Rb, (Figure 5B).
PD0166285 repressed cyclin D transcription
We next investigated cyclin D mRNA transcription, using
RT-PCR. Cyclin D mRNA transcription decreased after 4
hours of treatment with PD0166285 (Figure 6A). We then
examined the transcription of cyclin D mRNA more quan-
titatively by real-time PCR. Expression of cyclin D mRNA
decreased to 42.1% of baseline levels at 4 hours (Figure
6B). Thus, PD0166285 down-regulated the transcription
of cyclin D mRNA within 4 hours, a time course similar to
that of microtubule destabilization.
Discussion
We studied the mechanisms by which the Wee1 inhibitor
PD0166285 suppressed growth of the B16 mouse
melanoma cell line. In previous reports, G2 checkpoint
abrogation by 0.5 μM of PD0166285 was demonstrated
to kill cancer cells [18,21]. Deregulated cell cycle progres-
sion ultimately may have damaged the cancer cells. When
those authors examined toxicity, the highest dose of
PD0166285 was 0.5 μM for exposure periods no more
than 6 hours in some cell lines. When we exposed the
hepatoma carcinoma cell line Hep3B to PD0166285, after
4 hours of treatment the Hep3B cells entered G1 arrest
and after 6 hours the cells floated in the medium [19]. B16
melanoma cell line cells entered G1 arrested after 4 hours
and the cells floated after 24 hours at 0.5 μM PD0166285.
B16 cells showed an arrested cell proliferation for 4 hours,
but no apoptosis was not observed after 24 hours of treat-
ment by 0.5 μM PD0166285. After 24 hours, the cell were
observed to be floating and dead (Figure 1A).
PD0166285 is the safe reagent. At least, 0.3 μM UCN-1
and 3 mM caffeine can induce the dephosphorylation of
cdc2-Ty15. PD0166285 can induce the dephosphoryla-
tion at 0.5 μM which is very small concentrations. Moreo-
ver, for an in vivo assay, we injected 500 μl of 20 μM
PD0166285 into the peritoneum cavity of B6 mice for 4
weeks. However the injected reagent was no negative
Effects of PD0166285 treatment on the suppression of cell proliferation and the cell cycle distributionFigure 1
Effects of PD0166285 treatment on the suppression of cell proliferation and the cell cycle distribution. A: The cells were har-
vested after treatment with (0, 0.5, 1.0, or 2.0 μM) PD0166285 (including DMSO vehicle) for the indicated times, and then the 
cells were counted. B: The cells were harvested after treatment with 0.5 μM for the indicated period, fixed, stained with PI, and 
analyzed for DNA content by flow cytometry. The percent of cells in the cell cycle after treatment were indicated on lower 
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PD0166285 might be therefore reagent with the peculiar-
ity and safe for normal cells.
We could not investigate a human melanoma cell line and
other cell lines, but such cell arrest and cell death could be
observed in some cell lines including a human hepatoma
cell line in the previous papers[18,19]. 0.5 μM
PD0166285 thus appears to induce cell arrest in many
cancer cell lines.
We found that PD0166285 rapidly brought about pro-
gression to cell cycle arrest in early G1 after a cell division
phase. At a concentration of 0.5 μM, PD0166285 inhib-
ited cdc2 inaction by phosphorylation at Ty15 (Figure
3A). It is reported that kinase activity of Wee1 is regulated
by self-phosphorylation. At 4 hours, expression of Wee1
showed little change. Cyclin B protein expression was not
seen by immunofluorescence microscopy (Figure 3B).
B16 cells arrested in the early G1 phase at 4 hours, accord-
ing to flow cytmetry (Figure 1). But cell death was not seen
until 4 hours of exposure to PD0166285 at 0.5 μM.
These findings indicate that the effect of 0.5 μM
PD0166285 for G1 cell arrest is Wee1 activity in an unu-
sual way. The Wee1 knock down (siRNA experiment)
might thus help to elucidate the direct or non-specific
response. However, further investigation is called for.
Effects of PD0166285 treatment on the microtubule stabilizationFigure 2
Effects of PD0166285 treatment on the microtubule stabilization. A: Cells were fixed and stained with PI (red) and anti-α-tubu-
lin antibody followed by FITC-labeled secondary antibody (green). Shown is a typical image under laser confocal microscopy. B: 
magnifications at 0 h, 2 h, and 4 h. Bar: 10 μmPage 6 of 11
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of treatment with 0.5 μM PD0166285. Observed by
immunofluorescence microscopy, microtubule polymeri-
zation failed to occur in B16 cells treated with
PD0166285. To clarify these observations we carried out
immunofluorescence microscopy (Figure 2B), and flow
cytometry (data not shown) after 2 hours of exposure. The
cells in resting phase showed no cell cycle progression,
and no clearly evident abnormalities. However, microtu-
bule polymerization was blocked in all cells after 4 hours
of PD0166285 treatment. Cyclin D was suppressed at 4
hours. PD0166285 treatment for 4 hours suppressed cyc-
lin D protein expression and transcription. These observa-
tions indicated that PD0166285 arrested the cell cycle in
the early G1 phase, accompanied by inhibition of micro-
tubule stabilization and suppression of cyclin D expres-
sion by imperfect adhesion.
Changes in cell architecture are required for progression
through the cell cycle. The most dramatic of these is a
complete recognition of the cytoskeleton triggered by pro-
teins phosphorylated by cyclinB-cdc2 such as the kinesin-
like motor proteins required for proper assembly of
mitotic spindle [22,23], as well as the actin binding pro-
tein caldesmon and several regulators of small GTPases,
Rho and CDC42, that mediate rearrangements of the actin
cytoskeleton during mitosis [24-26]. Recent data have
indicated that plasma membrane lipid rafts are involved
in signal transduction events; raft formation is initiated by
cell adhesion to the extracelluler matrix, which is medi-
ated by transmembrane proteins called integrins [27-29].
Lipid rafts are directed by integrins to target Rho and Rac
GTPases. Microtubule stabilization is regulated by Rho-
mDia signaling and Rac-PAK signaling [30], which there-
fore occur downstream of integrin-mediated cell adhesion
via lipid raft formation. Focal adhesion kinase (FAK) has
been described as a critical mediator of integrin signaling,
allowing FAK to influence a variety of processes, including
the broadening of the cell attachment, migration, survival
and cycle progression.
Cyclin D expression begins to become evident after cell
adhesion. Two pathways separately act on cyclin D expres-
sion at the early G1 and middle G1 phase. Early in G1,
integrin-Rac is important for cyclin D expression when
cell cycling is initiated after cell adhesion. Rac was
reported to stimulate the expression of CCND1 mRNA in
both fibroblasts and epithelial cells [31]. NF-κB has been
implicated as Rac effectors [32,33]. Although the relation-
ship between reactive oxygen species and cyclin D1 has
yet to be elucidated, human and rodent CCND1 promot-
ers contain functional NF-κB binding sites. In the mid G1
phase, some hours after the early G1 phase, several studies
have shown that sustained signaling from extracelluler
signal regulated kinases (ERK) stimulates the production
of CCND1 mRNA in mesenchymal cells. Integrin signal-
Effects of PD0166285 on the G2 phaseFigure 3
Effects of PD0166285 on the G2 phase. A: Immunoblot analysis of anti-cdc2, anti-phosphorylated cdc2-tyr15, and Wee1 was 
performed in lysates of with 0.5 μM PD0166285 treated for 0 h, 2 h, or 4 h. B: Subcellular location of cyclin B was observed. 
After 4 h of treatment with 0.5 μM PD0166285, cells were fixed and doubly stained for immunofluorescence with PI (red) and 
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early G1, is suppressed in the mid G1 phase [34]. Instead,
various growth factors act via ERK to up-regulate cyclin D
expression in mid G1 [35].
PD0166285 inhibited microtubule polymerization while
suppressing cyclin D expression. Finally, Rb demonstrated
inactive by dephosphorylation (Figure 5B), and the cell
cycle was completely arrested in early G1 [36]. Impor-
tantly, adhesion-related molecules such as integrin, Rho,
Rac, and FAK are highly complex and involve considera-
ble cross talk in signaling [37]. Rho, Rac, and FAK activity
were not analyzed in this study, but will be investigated in
the future.
Microtubule stabilization failure might involve Wee1
inactivation or a direct drug effect of PD0166285 on
microtubules. The role of Wee1 is not completely under-
stood. Our result suggested there was Wee1 colocalization
with α-tubulin (Figure 4B), as has been suggested previ-
ously [38]. Wee1 might affect tubulin directly, while other
reports have indicated a relationship between Wee1 and
the Src homologue protein Crk, which is associated with
FAK signaling [39,40]. Recently, a novel Wee1 inhibitor
related to compounds showing Src kinase homology was
reported to arrest the cell cycle in the S phase[41]. Wee1
might act upon FAK signaling with respect to signal trans-
mission involving a Src-homology protein. As a result,
Wee1 may be more than a G2 checkpoint nullifier, since
it also affects cell adhesion molecules.
Conclusion
In this study we demonstrated a novel cell cycle-regulating
effect of the Wee1 inhibitor PD0166285, a pyrido (2,3-d)
Effects of PD0166285 on the cellular location of Wee1 and adhesionFigure 4
Effects of PD0166285 on the cellular location of Wee1 and adhesion. A: After 4 h of PD0166285 treatment, cells were fixed 
and doubly stained for immunofluorescence with PI (red) and anti-Wee1 (green). B: After 4 h of 0.5 μM PD0166285 treatment, 
morphologic changes and double stained with anti-α-tubulin (green) and anti-Wee1 (red) were observed. Shown are typical 
images obtained by laser confocal microscopy. Bar: 10 μm.
0 h
Red; PI Green; Wee1 
4 h
0 h 4 h
Red; Wee1 Green; α-tubulin
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Effects of PD0166285 on expression related protein of cell cycle regulatorsFigure 5
Effects of PD0166285 on expression related protein of cell cycle regulators. A: Lysates (30 μg) were prepared from cells after 
treatment with 0.5 μM PD0166285 for the indicated period (0 h, 2 h and, 4 h) were subjected to immunoblot analysis with 
anti-cyclin D, anti-cyclin E, anti-p16, anti-p21, and anti-p27 antibodies. B: Cell lysates after treatment with 0.5 μM PD0166285 
for long periods treatment; (0 h, 4 h, and 24 h) were subjected to an immunoblot analysis with Anti-Rb antibody and cell cycle 
suppression directly molecule p21 and p27.













Effects of PD0166285 on cyclin D transcriptionFigure 6
Effects of PD0166285 on cyclin D transcription. A: RT-PCR analysis of cyclin D mRNA in 0.5 μM PD0166285 treated cells. RT 
yielded a cDNA template for PCR amplification with specific-specific primers. GAPDH expression was analyzed as a control. B: 
Quantitative real-time PCR analysis of specific mRNA after treatment with 0.5 μM PD0166285. Three independent experi-
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BMC Cancer 2006, 6:292 http://www.biomedcentral.com/1471-2407/6/292pyimidine, in B16 mouse melanoma cells. PD0166285
inhibited Wee1 function, abrogated the G2 checkpoint,
and induced early cell division. PD0166285 blocked
microtubule stabilization, and inhibited cyclin D expres-
sion. These effects thus suggest that Wee1 inhibitor may
thus be a potentially effective anti-cancer drug.
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